Cerevance Media Center

Current News

January 27, 2023

Cerevance Announces Publication in Organic Process Research and Development

Cerevance today announced the publication in Organic Process Research and Development entitled, “Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor”.

READ FULL

January 9, 2023

Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia

  • CVN766 was well tolerated with no serious adverse events
  • CVN766, which has >1000-fold selectivity for the orexin 1 receptor, was well tolerated and showed no evidence of somnolence
  • Data supports once a day dosing of CVN766 in future studies
READ FULL

November 30, 2022

Cerevance to Present Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases – Biology and Therapeutics Conference and Publication in Neuropharmacology

  • Presentation highlights a novel target identified for Alzheimer’s disease using Cerevance’s proprietary NETSseq platform
  • Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated positive results in human and mouse cell based and electrophysiology assays relevant to neuroinflammation in neurodegenerative disease
  • Data has been concurrently published in the peer-reviewed journal, Neuropharmacology
READ FULL

August 9, 2022

Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease

Cerevance today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.

READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

May 16, 2023

Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)

Date:
Tuesday, May 30, 2023
Time:
2:00pm – 4:00pm
Location:
Miami, Florida
Media:
Oral Presentation
Read full

May 9, 2023

Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development

Date:
Monday, May 15, 2023
Time:
Check schedule for times
Location:
British Columbia, Canada
Media:
Presentation
Read full

May 8, 2023

2023 RBC Capital Markets Global Healthcare Conference

Date:
Tuesday, May 16, 2023
Time:
9:00 – 9:25am ET
Location:
New York, NY
Media:
Presentation
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

August 14, 2023

A Covalent Binding Mode of a Pyrazole-Based CD38 Inhibitor

Doyle, K., Roberts, M., Harvey, J, Hewer, R., Zebisch, M., Rangel, V., Gu, M., Wu, Y., Yang, L., Carlton, M., Dawson, L. & Bürli, R.

Viewview

October 15, 2018

Species and Cell-Type Properties of Classically Defined Human and Rodent Neurons and Glia

Xu, X., Stoyanova, E.I., Lemiesz, A.E., Xing, J., Mash, D.C., Heintz, N.

Viewview